Etcamah Tablet, Film Coated
Product Images NDC 0310-0075

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Etcamah (NDC 0310-0075). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Astrazeneca Pharmaceuticals Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Botttle_75_mg (Botttle 75 mg)

ETCAMAH 75 mg (camizestrant) tablets film coated oral tablets label by AstraZeneca Pharmaceuticals LP. The label states 28 tablets per bottle with storage instructions to keep in the original bottle with desiccant. The label includes NDC 0310-0075-01 and features the AstraZeneca logo.*

FDA Label Image

Chemical Structure (Chemical Structure)

Chemical structure diagram of camizestrant, the active ingredient in ETCAMAH 75 mg film-coated tablets. The diagram shows the molecular arrangement and bonding of camizestrant with fluorine atoms and nitrogen-containing rings.*

FDA Label Image

Figure_1 (Figure 1)

A Kaplan-Meier curve showing the probability of progression-free survival over time in months from randomization. The graph compares ETCAMAH (camizestrant) plus a CDK4/6 inhibitor versus an AI plus a CDK4/6 inhibitor, displaying higher survival probability for the ETCAMAH group. A patient risk table is included below the x-axis for both treatment groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.